The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN1582325     (E)-7-[2-cyclopropyl-4-(4...

Synonyms: CID192707, DCL000848, LS-187750, AKOS015896459, CID10219163, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Pitavastatin


High impact information on Pitavastatin


Chemical compound and disease context of Pitavastatin


Biological context of Pitavastatin


Anatomical context of Pitavastatin


Associations of Pitavastatin with other chemical compounds


Gene context of Pitavastatin


Analytical, diagnostic and therapeutic context of Pitavastatin


  1. Alterations of interneurons of the gerbil hippocampus after transient cerebral ischemia: effect of pitavastatin. Himeda, T., Hayakawa, N., Tounai, H., Sakuma, M., Kato, H., Araki, T. Neuropsychopharmacology (2005) [Pubmed]
  2. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Zambarakji, H.J., Nakazawa, T., Connolly, E., Lane, A.M., Mallemadugula, S., Kaplan, M., Michaud, N., Hafezi-Moghadam, A., Gragoudas, E.S., Miller, J.W. Invest. Ophthalmol. Vis. Sci. (2006) [Pubmed]
  3. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Saito, Y., Yamada, N., Teramoto, T., Itakura, H., Hata, Y., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., Ogawa, N., Goto, Y. Atherosclerosis (2002) [Pubmed]
  4. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., Sugiyama, Y. Mol. Pharmacol. (2005) [Pubmed]
  5. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Chung, J.Y., Cho, J.Y., Yu, K.S., Kim, J.R., Oh, D.S., Jung, H.R., Lim, K.S., Moon, K.H., Shin, S.G., Jang, I.J. Clin. Pharmacol. Ther. (2005) [Pubmed]
  6. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-{gamma}, and aortic stiffness in hypercholesterolemia. Umeji, K., Umemoto, S., Itoh, S., Tanaka, M., Kawahara, S., Fukai, T., Matsuzaki, M. Am. J. Physiol. Heart Circ. Physiol. (2006) [Pubmed]
  8. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. Yoshitomi, Y., Ishii, T., Kaneki, M., Tsujibayashi, T., Sakurai, S., Nagakura, C., Miyauchi, A. J. Atheroscler. Thromb. (2006) [Pubmed]
  9. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Tsubouchi, H., Inoguchi, T., Sonta, T., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto, H., Utsumi, H., Nawata, H. Free Radic. Biol. Med. (2005) [Pubmed]
  10. Pitavastatin prevents NMDA-induced retinal ganglion cell death by suppressing leukocyte recruitment. Nakazawa, T., Takahashi, H., Nishijima, K., Shimura, M., Fuse, N., Tamai, M., Hafezi-Moghadam, A., Nishida, K. J. Neurochem. (2007) [Pubmed]
  11. Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP. Zanotti, I., Potì, F., Favari, E., Steffensen, K.R., Gustafsson, J.A., Bernini, F. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  12. Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase. Fujino, M., Miura, S., Matsuo, Y., Tanigawa, H., Kawamura, A., Saku, K. Atherosclerosis (2006) [Pubmed]
  13. Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. Kikuchi, R., Kusuhara, H., Abe, T., Endou, H., Sugiyama, Y. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  14. Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. Maeda, K., Yasunari, K., Sato, E.F., Inoue, M. Atherosclerosis (2005) [Pubmed]
  15. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Yokoyama, T., Miyauchi, K., Kurata, T., Satoh, H., Daida, H. Atherosclerosis (2004) [Pubmed]
  16. HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Narumiya, H., Sasaki, S., Kuwahara, N., Irie, H., Kusaba, T., Kameyama, H., Tamagaki, K., Hatta, T., Takeda, K., Matsubara, H. Cardiovasc. Res. (2004) [Pubmed]
  17. Vascular Lipotoxicity: Endothelial Dysfunction via Fatty-Acid-Induced Reactive Oxygen Species Overproduction in Obese Zucker Diabetic Fatty Rats. Chinen, I., Shimabukuro, M., Yamakawa, K., Higa, N., Matsuzaki, T., Noguchi, K., Ueda, S., Sakanashi, M., Takasu, N. Endocrinology (2007) [Pubmed]
  18. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. Hirano, M., Maeda, K., Hayashi, H., Kusuhara, H., Sugiyama, Y. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  19. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Maejima, T., Yamazaki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., Saito, Y. Biochem. Biophys. Res. Commun. (2004) [Pubmed]
  20. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Kibayashi, E., Urakaze, M., Kobashi, C., Kishida, M., Takata, M., Sato, A., Yamazaki, K., Kobayashi, M. Clin. Sci. (2005) [Pubmed]
  21. A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced apoptosis in human vascular smooth muscle cells. Tsujimoto, A., Takemura, G., Mikami, A., Aoyama, T., Ohno, T., Maruyama, R., Nakagawa, M., Minatoguchi, S., Fujiwara, H. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  22. Pitavastatin inactivates NF-kappaB and decreases IL-6 production through Rho kinase pathway in MCF-7 cells. Wang, J., Kitajima, I. Oncol. Rep. (2007) [Pubmed]
  23. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Wang, J., Tokoro, T., Matsui, K., Higa, S., Kitajima, I. Life Sci. (2005) [Pubmed]
  24. Pitavastatin inhibits cardiac hypertrophy in a rat model of progressive renal injury. Takahashi, H., Takeishi, Y., Arimoto, T., Shishido, T., Konta, T., Koyama, Y., Niizeki, T., Kubota, I. J. Cardiovasc. Pharmacol. (2005) [Pubmed]
  25. Protective effect of pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, on ischemia-induced neuronal damage. Kurosaki, R., Muramatsu, Y., Kato, H., Araki, T. Neurol. Res. (2004) [Pubmed]
WikiGenes - Universities